Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment

ConclusionIt was suggested that sequential therapy using ZOL could suppress the decrease of BMD, and increase of BTM, if the period of Dmab administration was less than 3 years.

http://link.springer.com/10.1007/s00774-020-01126-w

Source: Journal of Bone and Mineral Metabolism - July 11, 2020 Category: Orthopaedics Source Type: research